Apart from the type and number of TILs, the expression of immune checkpoint genes on tumor cells, such as PD-L1 and CTLA-4, have been reported as predictive biomarkers for the therapeutic efficacy of immune checkpoint inhibitors in some cancers [30,31]. This evidence concerns the gene CTLA4 and cancer.